Background. Commercially available tests for Clostridium difficile infection (CDI) make test selection by the laboratory difficult due to the following unsatisfactory characteristics: long turnaround time, poor sensitivity, and/or poor specificity. The Singulex Clarity® C. diff toxins A/B assay (in development) is a rapid and automated immunoassay for the detection of C. difficile toxins A and B in stool, with analytical limits of detection for toxins A and B at 2.0 and 0.7 pg/mL, respectively. In this multicenter study, the clinical performance of the Singulex Clarity C. diff toxins A/B assay was compared with standalone PCR, a multistep algorithm with enzyme immunoassay (EIA) and PCR, and cell cytotoxicity neutralization assay (CCNA).
Background. Overtesting and overdiagnosis of Clostridium difficile infection (CDI) are increasingly recognized as potentially avoidable causes for unnecessary treatment and cost. Reducing inappropriate testing through diagnostic stewardship may improve C. difficile test utilization. However, the safety of these interventions is not well understood, despite the potential risk for missed or delayed diagnosis. A computerized clinical decision support (CCDS) tool was implemented at a 619-bed tertiary care hospital as part of a multifaceted effort to reduce inappropriate C. difficile testing. The intervention was associated with reductions in tests (41%) and hospital-onset CDI events (31%). We sought to examine patient outcomes associated with the intervention.
Methods. The CCDS was designed to identify patients with a prevented test if a provider initiated the CCDS and aborted the order. Outcomes of patients with either a prevented or negative nucleic acid amplification test (NAAT) were compared retrospectively. A logistic regression model was created to evaluate the association between a prevented test attempt and serious adverse events. Patients with a subsequent positive result within 7 days of the initial trigger and those treated with CDI-effective antibiotics underwent chart review.
Results. Multivariate analysis of 637 cases (490 negative, 147 prevented) showed that a prevented test was not associated with the primary composite outcome (inpatient mortality or ICU-transfer) compared with a negative test (adjusted odds ratio, 0.912; 95% CI 0.513-1.571). Prevented tests were associated with shorter length of stay and similar rates of CDI-related complications. Eleven (7.5%) had a subsequent positive CDI, four within 30 minutes of the prevented test, suggesting nonsignificant delay in testing. Of the remaining seven patients, case review confirmed that five did not meet testing criteria while two met testing criteria at the time of the prevented test. No serious adverse events attributable to delayed CDI diagnoses or unjustified CDI treatment were identified by individual case review.
Conclusion. CCDS-based diagnostic stewardship for CDI may be both a safe and effective means to reduce inappropriate testing.
Disclosures. All authors: No reported disclosures. Methods. Retrospective analysis of children <3 years with GI illness and FGP CD+ results between September 2016 and April 2018. CD PCRs for toxin B and GDH, CD EIA for toxin A/B/GDH were performed on convenience samples of frozen aliquots in Cary Blair. Physician request for release of CD results was used as a surrogate of possible role of CD on GI illness.
Algorithmic Release of Clostridium difficile PCR Results From a Multiplex Gastrointestinal (GI) Panel in
Results. Of 5,990 FGP, 2,267 (38%) were in children <3 years: 619 (27%) were CD+. Of these 619, 602 (97%) were not reported per algorithm. 62% (386/619) of CD+ samples had copathogens detected; enteropathogenic Escherichia coli and norovirus most frequently. For CD PCRs and EIA performed in subset of 49 CD+, mean cycle threshold values (Cts) for toxin B were evaluated (Table 1) . Of 48 samples with detectable CD by toxin B PCR, 14 (29%) had both GDH and toxin B detected, 24 (51%) had only GDH detected, and 9 (19%) had neither GDH nor toxin B detected.
Conclusion. Only 3% of FGP CD results in children <3 years were released per physician request, suggesting limited clinical significance. A copathogen was detected in 62% of CD+ samples that may explain illness. Among evaluable samples, only 28.6% of CD+ had both GDH and toxin detected by EIA, possibly indicating low specificity of CD PCR. Ongoing testing and prospective studies are warranted to determine the validity of our algorithm and if semi-quantitative PCR or EIA can be useful to identify when CD detection by FGP in children <3 years is clinically significant. Background. Studies have shown that toxin detection identifies those who require treatment for C. difficile infection (CDI) and free toxin can be predicted with high negative predictive value from PCR cycle threshold (CT). CT-toxin was introduced at our institution in two phases: from October 2016 to October 2017, CT-toxin was reported with the PCR result (split reporting) and CDI therapy was discouraged if CT-toxin was negative (PCR+/CTtox−). Interim analysis showed that CDI treatment had no effect on outcomes in these CTtox− patients, so starting November 2017, only CT-toxin was reported. Outcomes in PCR+/CTtox− patients treated during split reporting and untreated during the toxin-only period are detailed here.
Methods. Patients tested from October 2016 to February. 2018 with a positive Xpert tcdB PCR (Cepheid, Sunnyvale, CA) and CTtox− result were included. Clinical data were collected by retrospective chart review in the split reporting period and prospective review in the toxin-only period and analyzed using SPSS at α = 0.01.
Results. Of 186 unique PCR+/CTtox-patients during split reporting, 99 (53%) were treated, compared with 6 (12%, n = 51) in the toxin-only period (P < 0.001). In comparing treated patients during split reporting to untreated patients during toxin-only reporting (n = 45), there were no significant differences in age, sex, prior antibiotic use, CDI in the previous 6 months, Charlson Comorbidity Index, patient location, immune status, or data at testing, including WBC count, creatinine, albumin, and stools/day. There were no cases of fulminant CDI in either group and no difference in outcomes (table) .
Conclusion. Reporting of CT-toxin alone significantly reduced treatment for CDI compared with split reporting in CTtox− patients with no increase in adverse outcomes in short-term follow-up. Further study is needed to confirm these findings in a larger cohort. 
